Your Article Summary
Examination of the Relationship Between Oncology Drug Labeling Revision Frequency and FDA Product Categorization
American Journal of Public Health, 07/01/09
Berlin RJ - Accelerated approval products are approved based on surrogate endpoints; this approval process anticipates subsequent labeling refinement. Priority review products, however, are approved through a process that is ostensibly as rigorous as traditional review. Their higher than expected label revision rate may suggest deficiencies in the FDA’s current priority review evaluation processes.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09
Article Search
Sponsor


See Latest Articles


